What is the differential diagnosis for acute erythematous, pustular lesions on the nasal tip and bridge in an elderly female receiving chemotherapy?

Differential Diagnosis of Acute Erythematous Pustular Lesions on Nasal Tip and Bridge in Elderly Female on Chemotherapy

The most likely diagnosis is drug-induced papulopustular eruption (acneiform rash) from targeted chemotherapy agents, particularly EGFR inhibitors or MEK inhibitors, though you must also urgently exclude bacterial superinfection, acute generalized exanthematous pustulosis (AGEP), and invasive fungal infection given the immunocompromised state.

Primary Differential Considerations

1. Drug-Induced Papulopustular Eruption (Most Common)

This is the most frequent dermatological adverse event in oncology patients receiving targeted therapies 1. The presentation matches classic features:

• Incidence: 75-90% of patients on EGFR inhibitors (erlotinib, afatinib, gefitinib, cetuximab, panitumumab) and 74-85% on MEK inhibitors (trametinib, binimetinib, cobimetinib) 1
• Timing: Develops within days to weeks after therapy initiation 1
• Distribution: Characteristically affects sebaceous-rich areas—face (forehead, nose, cheeks), then potentially chest and upper back 1
• Pathophysiology: Inflammatory process with impaired antimicrobial peptide expression, creating susceptibility to secondary bacterial infection 1

Critical point: Up to 38% develop bacterial colonization or superinfection 1, which you must actively exclude.

2. Bacterial Superinfection of Drug-Induced Rash

Given the pustular nature and immunocompromised state:

• The underlying drug-induced rash creates impaired host defense 1
• Bacterial superinfection occurs in up to 38% of cases 1
• Action required: Obtain bacterial culture from pustules to guide antibiotic therapy if infection confirmed

3. Acute Generalized Exanthematous Pustulosis (AGEP)

A serious drug reaction that can occur with chemotherapy agents 2, 3:

• Distinguishing features: High fever (>38°C), rapid onset (1-4 days post-medication), sterile pustules on erythematous base, followed by desquamation 3
• Mortality: ~5% 3
• Recent case: Documented with immunotherapy/chemotherapy combination in lung cancer patient 2
• Key difference from acneiform rash: More generalized distribution, acute systemic symptoms, and rapid progression

4. Primary Cutaneous Aspergillosis

Must be excluded urgently in neutropenic patients 4:

• High-risk scenario: Neutropenia + any nasal trauma/packing + facial erythema
• Presentation: Rapidly progressive paranasal erythematous lesion evolving to violaceous necrotic plaque 4
• Action required: If patient is neutropenic or lesion shows necrosis/violaceous color, obtain urgent fungal culture and consider tissue biopsy
• Treatment: Requires immediate voriconazole 4

5. Cutaneous Candidiasis

Documented in chemotherapy patients 5:

• Can present as pustular lesions during chemotherapy
• Risk of disseminated disease in immunocompromised patients
• Requires fungal culture and blood cultures if systemic symptoms present

Critical Clinical Algorithm

Immediate assessment priorities:

1. Check absolute neutrophil count (ANC)

   • If neutropenic: Invasive fungal infection becomes top concern 4

2. Assess lesion characteristics:

   • Violaceous/necrotic appearance → urgent fungal workup 4
   • Follicular pustules on erythema without necrosis → drug-induced rash most likely 1

3. Check for systemic symptoms:

   • High fever (>38°C) + rapid generalization → consider AGEP 2, 3
   • Fever + neutropenia + necrotic lesion → invasive fungal infection until proven otherwise 4

4. Identify specific chemotherapy regimen:

   • EGFR inhibitors (erlotinib, gefitinib, cetuximab, etc.) → 75-90% develop acneiform rash 1
   • MEK inhibitors (trametinib, binimetinib, cobimetinib) → 74-85% develop similar rash 1
   • Recent antibiotic exposure → consider AGEP 3

Diagnostic Workup

Essential investigations:

• Bacterial culture from pustules (to identify superinfection) 1
• Complete blood count with differential (assess neutropenia)
• Fungal culture and KOH preparation if neutropenic or atypical features 4
• Skin biopsy if diagnosis unclear: Shows periadnexal inflammatory infiltrate in drug-induced rash 1

Common Pitfalls to Avoid

1. Assuming all pustular rashes in oncology patients are drug-induced: Always exclude infection, especially in neutropenic patients 4

2. Missing bacterial superinfection: The drug-induced rash itself impairs antimicrobial defenses, making superinfection common (38%) 1

3. Delaying antifungal therapy in neutropenic patients: Primary cutaneous aspergillosis progresses rapidly and requires immediate treatment 4

4. Not recognizing AGEP: This has 5% mortality and requires drug discontinuation 3

5. Overlooking rare malignancies: While less likely with acute onset, extranodal NK/T-cell lymphoma can present with nasal destructive lesions 6, 7, though typically more chronic

Summary of Most Likely Diagnoses (in order of probability)

1. Drug-induced papulopustular eruption (75-90% incidence with targeted agents) 1
2. Bacterial superinfection of drug-induced rash (38% of cases) 1
3. AGEP (if fever and rapid generalization present) 2, 3
4. Primary cutaneous aspergillosis (if neutropenic) 4
5. Cutaneous candidiasis (documented in chemotherapy patients) 5